Targeting YAP and Hippo signaling pathway in liver cancer

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 8, 2010, Pages 855-868

  Liu, Angela M ^a,b   Xu, Michelle Z ^c   Chen, Jinfei ^c   Poon, Ronnie T ^b   Luk, John M ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NANJING MEDICAL UNIVERSITY   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Hippo pathway; Liver cancer; Molecular therapeutics; YAP oncogene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA FETOPROTEIN; AMG 479; BORTEZOMIB; CARBOPLATIN; CGP 6984; CGP 69846A; CP 751871; DACHSOUS PROTEIN; EXPANDED PROTEIN; HIPPO PROTEIN; HOMOTHORAX PROTEIN; KIBRA PROTEIN; MERLIN; MICRORNA; NEUROFIBROMIN; PACLITAXEL; PDZ PROTEIN; PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TAMOXIFEN; TEASHIRT PROTEIN; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; YES ASSOCIATED PROTEIN; YORKIE PROTEIN;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DROSOPHILA; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROSTATE CANCER; PROTEIN BINDING; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; DROSOPHILA PROTEINS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77954770827     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.499361     Document Type: Review

References (145)

1. Oh H, Irvine KD. Yorkie: the final destination of Hippo signaling. Trends Cell Biol 2010: published online 7 May 2010, doi:10.1016/j.tcb.2010.04.005
2. Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol 2007;8:613-621
3. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006;103:12405-12410
4. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-1267
5. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007;21:2747-2761
6. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130:1120-1133
7. Justice RW, Zilian O, Woods DF, et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 1995;9:534-46
8. Tapon N, Harvey KF, Bell DW, et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002;110:467-478
9. Kango-Singh M, Nolo R, Tao C, et al. Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development 2002;129:5719-5730
10. Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 2003;114:457-67
11. Pantalacci S, Tapon N, Leopold P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 2003;5:921-927
12. Udan RS, Kango-Singh M, Nolo R, et al. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 2003;5:914-920
13. Wu S, Huang J, Dong J, Pan D. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003;114:445-456
14. Lai ZC, Wei X, Shimizu T, et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 2005;120:675-685
15. Huang J, Wu S, Barrera J, et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005;122:421-434
16. Oh H, Irvine KD. In vivo analysis of Yorkie phosphorylation sites. Oncogene 2009;28:1916-1927
17. Goulev Y, Fauny JD, Gonzalez-Marti B, et al. SCALLOPED interacts with YORKIE, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila. Curr Biol 2008 18:435-441
18. Wu S, Liu Y, Zheng Y, et al. The Hippo growth-regulatory pathway. Dev Cell 2008;14:388-398
19. Peng HW, Slattery M, Mann RS. Transcription factor choice in the Hippo signaling pathway: homothorax and yorkie regulation of the microRNA bantam in the progenitor domain of the Drosophila eye imaginal disc. Genes Dev 2009;23:2307-2319
20. Thompson BJ, Cohen SM. The Hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in Drosophila. Cell 2006;126:767-774
21. Nolo R, Morrison CM, Tao C, et al. The bantam microRNA is a target of the hippo tumor-suppressor pathway. Curr Biol 2006;16:1895-1904
22. Hamaratoglu F, Willecke M, Kango-Singh M, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006;8:27-36
23. Genevet A, Wehr MC, Brain R, et al. Kibra is a regulator of the Salvador/ Warts/Hippo signaling network. Dev Cell 2010;18:300-308
24. Bennett FC, Harvey KF. Fat cadherin modulates organ size in Drosophila via the Salvador/Warts/Hippo signaling pathway. Curr Biol 2006;16:2101-2110
25. Silva E, Tsatskis Y, Gardano L, et al. The tumor-suppressor gene fat controls tissue growth upstream of expanded in the hippo signaling pathway. Curr Biol 2006;16:2081-2089
26. Willecke M, Hamaratoglu F, Kango-Singh M, et al. The fat cadherin acts through the hippo tumor-suppressor pathway to regulate tissue size. Curr Biol 2006;16:2090-2100
27. Mahoney PA, Weber U, Onofrechuk P, et al. The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell 1991;67:853-868
28. Cho E, Irvine KD. Action of fat, four-jointed, dachsous and dachs in distal-to-proximal wing signaling. Development 2004;131:4489-4500
29. Brittle AL, Repiso A, Casal J, et al. Four-jointed modulates growth and planar polarity by reducing the affinity of dachsous for fat. Curr Biol 2010;20:803-810
30. Simon MA, Xu A, Ishikawa HO, Irvine KD. Modulation of FAt: dachsous binding by the cadherin domain kinase four-jointed. Curr Biol 2010;20:811-817
31. Mao Y, Rauskolb C, Cho E, et al. Dachs: an unconventional myosin that functions downstream of Fat to regulate growth, affinity and gene expression in Drosophila. Development 2006;133:2539-2551
32. Cho E, Feng Y, Rauskolb C, et al. Delineation of a fat tumor suppressor pathway. Nat Genet 2006;38:1142-1150
33. McCartney BM, Kulikauskas RM, LaJeunesse DR, Fehon RG. The neurofibromatosis-2 homologue, Merlin, and the tumor suppressor expanded function together in Drosophila to regulate cell proliferation and differentiation. Development 2000;127:1315-1324
34. Polesello C, Huelsmann S, Brown NH, Tapon N. The Drosophila RASSF homolog antagonizes the hippo pathway. Curr Biol 2006;16:2459-2465
35. Baumgartner R, Poernbacher I, Buser N, et al. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev Cell 2010;18:309-316
36. Yu J, Zheng Y, Dong J, et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell 2010;18:288-299
37. Grzeschik NA, Parsons LM, Allott ML, et al. Lgl, aPKC, and Crumbs regulate the Salvador/Warts/Hippo pathway through two distinct mechanisms. Curr Biol 2010;20:573-581
38. Robinson BS, Huang J, Hong Y, Moberg KH. Crumbs regulates Salvador/ Warts/Hippo signaling in Drosophila via the FERM-domain protein expanded. Curr Biol 2010;20:582-590
39. Tao W, Zhang S, Turenchalk GS, et al. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet 1999;21:177-181
40. Callus BA, Verhagen AM, Vaux DL. Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. FEBS J 2006;273:4264-4276
41. Chan EH, Nousiainen M, Chalamalasetty RB, et al. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 2005;24:2076-2086
42. Praskova M, Xia F, Avruch J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol 2008;18:311-321
43. Hao Y, Chun A, Cheung K, et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008;283:5496-5509
44. Lei QY, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008;28:2426-2436
45. Qi C, Zhu YT, Hu L, Zhu Y-J. Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer 2009;124:793-798
46. Lau YK, Murray LB, Houshmandi SS, et al. Merlin is a potent inhibitor of glioma growth. Cancer Res 2008;68(14):5733-5742
47. Morrison H, Sperka T, Manent J, et al. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 2007;67:520-527
48. Ikeda M, Kawata A, Nishikawa M, et al. Hippo pathway-dependent and -independent roles of RASSF6. Sci Signal 2009;2(90):ra59
49. Cooper WN, Hesson LB, Matallanas D, et al. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 2009;28:2988-2998
50. Sudol M, Bork P, Einbond A, et al. Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem 1995;270:14733-14741
51. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994;9:2145-2152
52. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003;278:33334-33341
53. Chen HI, Sudol M. The WW domain of Yes-associated protein binds aproline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA 1995;92:7819-7823
54. Bork P, Sudol M. The WW domain: A signalling site in dystrophin? Trends Biochem Sci 1994;19:531-533
55. Hoshino M, Qi M-L, Yoshimura N, et al. Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. J Cell Biol 2006;172:589-604
56. Zhao B, Li L, Tumaneng K, et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFbeta-TRCP. Genes Dev 2010;24:72-85
57. Kanai F, Marignani PA, Sarbassova D, et al. TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000;19:6778-6791
58. Oka T, Sudol M. Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. Genes Cells 2009;14:607-615
59. Danovi SA, Rossi M, Gudmundsdottir K, et al. Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis. Cell Death Differ 2008;15:217-219
60. Strano S, Monti O, Pediconi N, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol Cell 2005;18:447-459
61. Levy D, Adamovich Y, Reuven N, Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 2007;14:743-751
62. Zagurovskaya M, Shareef MM, Das A, et al. EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene 2009;28:1121-1131
63. Strano S, Munarriz E, Rossi M, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001;276:15164-15173
64. Zaidi SK, Sullivan AJ, Medina R, et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004;23:790-799
65. Teplyuk NM, Galindo M, Teplyuk VI, et al. Runx2 regulates G protein-coupled signaling pathways to control growth of osteoblast progenitors. J Biol Chem 2008;283:27585-27597
66. Vassilev A, Kaneko KJ, Shu H, et al. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/ Yes-associated protein localized in the cytoplasm. Genes Dev 2001;15:1229-1241
67. Zhang X, Milton CC, Humbert PO, Harvey KF. Transcriptional output of the Salvador/warts/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res 2009;69:6033-6041
68. Chen L, Chan SW, Zhang X, et al. Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev 2010;24:290-300
69. Li Z, Zhao B, Wang P, et al. Structural insights into the YAP and TEAD complex. Genes Dev 2010;24:235-240
70. Zhao B, Kim J, Ye X, et al. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res 2009;69:1089-1098
71. Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008;22:1962-1971
72. Chan SW, Lim CJ, Loo LS, et al. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 2009;284:14347-14358
73. Hong JH, Hwang ES, McManus MT, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005;309:1074-1078
74. Steinhardt AA, Gayyed MF, Klein AP, et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008;39:1582-1589
75. Fernandez-L A, Northcott PA, Dalton J, et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic Hedgehog-driven neural precursor proliferation. Genes Dev 2009;23:2729-2741
76. Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007;17:2054-2060
77. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009;115:4576-4585
78. Wang Y, Dong Q, Zhang Q, et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010: published online 10 March 2010, doi; 10.1111/j.1349-7006.2010. 01511
79. Lam-Himlin DM, Daniels JA, Gayyed MF, et al. The hippo pathway i human upper gastrointestinal dysplasia and carcinoma: A novel oncogenic pathway. Int J Gastrointest Cancer 2006;37:103-109
80. Yuan M, Tomlinson V, Lara R, et al. Yes-associated protein (YAP) functions a a tumor suppressor in breast. Cell Death Differ 2008;15:1752-1759
81. Kawahara M, Hori T, Chonabayashi K, et al. Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 2008;112:3856-3866
82. Basu S, Totty NF, Irwin MS, et al. Akt phosphorylates the Yes-associated protein YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003;11:11-23
83. Guo C, Tommasi S, Liu L, et al. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol 2007;17:700-705
84. Matallanas D, Romano D, Yee K, et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 2007;27:962-975
85. Oka T, Mazack V, Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem 2008;283:27534-27546
86. Tomlinson V, Gudmundsdottir K, Luong P, et al. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell Death and Dis 2010;1(2):e29
87. Yuan M, Luong P, Hudson C, et al. c-Abl phosphorylation of DeltaNp63alpha is critical for cell viability. Cell Death and Dis 2010;1(1):e16
88. St John MA, Tao W, Fei X, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999;21:182-186
89. Hisaoka M, Tanaka A, Hashimoto H. Molecular alterations of h-warts/ LATS1 tumor suppressor in human soft tissue sarcoma. Lab Invest 2002;82:1427-1435
90. Jiang Z, Li X, Hu J, et al. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006;56:450-458
91. Morinaga N, Shitara Y, Yanagita Y, et al. Molecular analysis of the h-warts/ LATS1 gene in human breast cancer. Int J Oncol 2000;17:1125-1129
92. Takahashi Y, Miyoshi Y, Takahata C, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005;11:1380-1385
93. Xia H, Qi H, Li Y, et al. LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 2002;21:1233-1241
94. Yang X, Li DM, Chen W, Xu T. Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G2/M arrest or apoptosis. Oncogene 2001;20(45):6516-6523
95. Seidel C, Schagdarsurengin U, Blumke K, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007;46:865-871
96. Minoo P, Zlobec I, Baker K, et al. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol 2007;20:331-338 (Pubitemid 46348330)
97. Zhou D, Conrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009;16:425-438
98. Lu L, Li Y, Kim SM, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010;107:1437-1442
99. Song H, Mak KK, Topol L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA 2010;107:1431-1436
100. Oh HJ, Lee KK, Song SJ, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006;66:2562-2569
101. Luo X, Li Z, Yan Q, et al. The human WW45 protein enhances MST1-mediated apoptosis in vivo. Int J Mol Med 2009;23:357-362
102. Lee JH, Kim TS, Yang TH, et al. A crucial role of WW45 in developing epithelial tissues in the mouse. EMBO J 2008;27:1231-1242
103. Lee KP, Lee JH, Kim TS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA 2010;107:8248-8253
104. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet 2009;373:1974-1986
105. Harvey K, Tapon N. The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer 2007;7:182-191
106. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010;394:623-627
107. Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev 2008;22:3320-3334
108. Ota M, Sasaki H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development 2008;135:4059-4069
109. Tian W, Yu J, Tomchick DR, et al. Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci USA 2010;107:7293-7298
110. Zhang H, Liu CY, Zha ZY, et al. TEAD Transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009;284:13355-13362
111. Wang MY, Chen PS, Prakash E, et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res 2009;69:3482-3491
112. Xie D, Nakachi K, Wang H, et al. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001;61:8917-8923
113. Dornhofer N, Spong S, Bennewith K, et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2006;66:5816-5827
114. Deng YZ, Chen PP, Wang Y, et al. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem 2007;282:36571-36581
115. Lay JD, Hong CC, Huang JS, et al. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 2007;67:3878-3887
116. Zhang YX, Knyazev PG, Cheburkin YV, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008;68:1905-1915
117. Alexia C, Fallot G, Lasfer M, et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004;68:1003-1015
118. Nussbaum T, Samarin J, Ehemann V, et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 2008;48:146-156
119. Zhang YC, Wang XP, Zhang LY, et al. Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 2006;12(25):3977-3982
120. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-2073
121. Karp DD, Pollak MN, Cohen RB, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009;4:1397-1403
122. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-2522
123. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13:16-24
124. Zhang J, Ji J-Y, Yu M, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 2009;11:1444-1450
125. Teraishi F, Guo W, Zhang L, et al. Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells. Cancer Res 2006;66:6072-6079
126. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-1309
127. Cho WJ, Shin JM, Kim JS, et al. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells 2009;28:521-527
128. Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res 2008;68:2789-2794
129. O'Neill E, Kolch W. Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle 2005;4:365-367
130. O'Neill E, Rushworth L, Baccarini M, Kolch W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 2004;306:2267-2270
131. Monia BP, Sasmor H, Johnston JF, et al. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 1996;93:15481-15484
132. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 2007;11:1587-1609
133. Gokhale PC, Zhang C, Newsome JT, et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res 2002;8:3611-3621
134. Rudin CM, Marshall JL, Huang CH, et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: A Phase I study. Clin Cancer Res 2004;10(21):7244-7251
135. Dritschilo A, Huang CH, Rudin CM, et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 2006;12:1251-1259
136. Kasid U, Dritschilo A. RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 2003;22:5876-5884
137. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005;14:313-328
138. Cinar B, Fang PK, Lutchman M, et al. The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J 2007;26:4523-4534
139. McClatchey AI, Giovannini M. Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev 2005;19:2265-2277
140. Ren A, Yan G, You B, Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res 2008;68:2266-2274
141. Graves JD, Gotoh Y, Draves KE, et al. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J 1998;17:2224-2234
142. Lee KK, Ohyama T, Yajima N, et al. MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J Biol Chem 2001;276:19276-19285
143. Li Y, Pei J, Xia H, et al. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003;22:4398-4405
144. Cantor JP, Iliopoulos D, Rao AS, et al. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer 2007;120:24-31
145. Dallol A, Agathanggelou A, Tommasi S, et al. Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res 2005;65:7653-7659